WBSCR9 Inhibitors
Chemical inhibitors of WBSCR9 operate through various mechanisms to inhibit its activity by disrupting the pathways that lead to its activation. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), an upstream activator of the Akt signaling pathway that is crucial for the phosphorylation and subsequent activation of WBSCR9. By inhibiting PI3K, these chemicals reduce Akt kinase activity, which is a necessary step for the phosphorylation of WBSCR9. Without this phosphorylation, WBSCR9 remains in a functionally inhibited state. Similarly, Spautin-1 promotes the degradation of PI3K, leading to a decrease in Akt-mediated WBSCR9 activation due to reduced PI3K levels. MK-2206 takes a more direct approach by allosterically inhibiting Akt, preventing WBSCR9 from becoming phosphorylated and activated.
In addition to these PI3K-Akt pathway inhibitors, other chemicals target the mTOR pathway, which is also related to the activation of WBSCR9. Rapamycin, for example, inhibits the mammalian target of rapamycin (mTOR), which has an impact on Akt signaling and, consequently, WBSCR9 activity. AZD8055 is another potent inhibitor of mTOR and by hindering mTOR activity, it suppresses the Akt pathway's influence on WBSCR9. Palomid 529 and PF-04691502 both disrupt the Akt/mTOR pathway, thus preventing the phosphorylation and activation of WBSCR9. Perifosine disrupts the Akt pathway differently by interfering with the membrane localization of Akt, which is required for its activation, leading to a decrease in WBSCR9 activity. Triciribine specifically inhibits Akt activation, which then leads to the functional inhibition of WBSCR9. Miltefosine inhibits Akt phosphorylation and GSK690693, as a pan-Akt inhibitor, prevents the activation of all Akt isoforms, thereby broadly inhibiting the activity of downstream proteins including WBSCR9. Each of these inhibitors, by acting at different points in the signaling pathways, ensures that the activation of WBSCR9 is effectively impeded.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are upstream of the Akt signaling pathway. WBSCR9 is known to be regulated by Akt phosphorylation. Inhibition of PI3K by wortmannin reduces Akt activity, which in turn can lead to the functional inhibition of WBSCR9 by preventing its phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, working similarly to wortmannin. By inhibiting PI3K, LY294002 decreases Akt kinase activity which is required for the phosphorylation and subsequent activation of several downstream proteins, including WBSCR9. The inhibition of this pathway leads to decreased WBSCR9 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation that also affects the Akt signaling pathway. By inhibiting mTOR, rapamycin can reduce the signaling through Akt, potentially inhibiting WBSCR9 activity due to decreased phosphorylation. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 promotes the degradation of PI3K, which is involved in the activation of Akt. By reducing PI3K levels, Spautin-1 indirectly inhibits the Akt-mediated activation of WBSCR9. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206 is an allosteric inhibitor of Akt. By directly inhibiting Akt, MK-2206 can prevent the phosphorylation of downstream targets including WBSCR9, leading to its functional inhibition. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) inhibits the Akt/mTOR pathway, which is implicated in the regulation of WBSCR9. Through inhibiting this pathway, P529 can prevent the functional activation of WBSCR9. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is a potent inhibitor of mTOR, which plays a role in the PI3K/Akt signaling pathway. By inhibiting mTOR, AZD8055 can suppress the Akt pathway and thus inhibit the downstream effects on WBSCR9. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $184.00 $321.00 | 1 | |
Perifosine is an Akt inhibitor that disrupts membrane localization of Akt, required for its activation. This leads to a decrease in phosphorylation of downstream targets, such as WBSCR9, resulting in its functional inhibition. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of Akt without affecting the PI3K or PDK1. This selective inhibition means that downstream proteins that depend on Akt for activation, such as WBSCR9, are functionally inhibited. | ||||||
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $79.00 | 8 | |
Miltefosine is an alkylphosphocholine compound that can inhibit Akt phosphorylation. By preventing Akt activation, miltefosine can functionally inhibit downstream proteins including WBSCR9. | ||||||